Needham & Company LLC Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price increased by equities researchers at Needham & Company LLC from $205.00 to $210.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price target suggests a potential upside of 50.35% from the company’s previous close.

Other equities analysts have also issued reports about the stock. Robert W. Baird raised their price target on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. HC Wainwright reissued a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Morgan Stanley upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. Piper Sandler reaffirmed an “overweight” rating and set a $163.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $179.00 target price on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. One analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $180.53.

Jazz Pharmaceuticals Trading Up 2.2 %

Shares of NASDAQ:JAZZ opened at $139.67 on Wednesday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals has a 52-week low of $99.06 and a 52-week high of $140.52. The stock has a market cap of $8.44 billion, a price-to-earnings ratio of 19.67, a PEG ratio of 1.04 and a beta of 0.56. The business has a 50-day moving average price of $125.42 and a 200-day moving average price of $118.44.

Insider Buying and Selling

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the sale, the chief executive officer now owns 425,525 shares of the company’s stock, valued at $52,522,550.75. The trade was a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders sold 5,053 shares of company stock valued at $617,442. 4.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Large investors have recently bought and sold shares of the company. Bessemer Group Inc. lifted its position in shares of Jazz Pharmaceuticals by 0.3% in the fourth quarter. Bessemer Group Inc. now owns 26,932 shares of the specialty pharmaceutical company’s stock valued at $3,317,000 after acquiring an additional 92 shares in the last quarter. CIBC Asset Management Inc raised its stake in Jazz Pharmaceuticals by 5.2% in the 4th quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company’s stock valued at $243,000 after purchasing an additional 97 shares during the last quarter. Synovus Financial Corp lifted its holdings in Jazz Pharmaceuticals by 0.5% in the 4th quarter. Synovus Financial Corp now owns 19,206 shares of the specialty pharmaceutical company’s stock valued at $2,365,000 after purchasing an additional 100 shares in the last quarter. Quarry LP boosted its stake in Jazz Pharmaceuticals by 6.3% during the 4th quarter. Quarry LP now owns 1,700 shares of the specialty pharmaceutical company’s stock worth $209,000 after purchasing an additional 100 shares during the last quarter. Finally, Quadrant Capital Group LLC grew its holdings in shares of Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock worth $25,000 after buying an additional 101 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.